Researchers at Fox Chase Cancer Center conducted the largest published, peer-reviewed, study to-date examining the short-term adverse effects of mRNA COVID-19 vaccination in patients with cancer—finding they experienced no more, and no different, side effects compared to non-cancer patients. PLYMOUTH MEETING, Pa., Feb. 7, 2022 /PRNewswire/ — New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from Fox Chase Cancer Center tracked short-term side-effects from more than 1,753 recipients of the Pfizer BNT162b2 vaccine, and found no additional reactions for patients undergoing active cancer treatment (surgery, chemotherapy, immunotherapy, or radiation therapy) or who had completed treatment. “Patients, their families, and their medical caregivers, should absolutely find these results reassuring. We surveyed almost 2,000 patients and found that cancer patients aren’t at risk for any unexpected reactions to being vaccinated compared to people without cancer,” said Eric M. Horwitz, MD, FABS, FASTRO, lead researcher and chair of the Department of Radiation Oncology, Lewis Katz School of Medicine at Temple University. “We now have the data and the clinical experience from thousands and thousands and thousands of cancer patients who have been vaccinated. We know that the mRNA vaccines are safe and are absolutely the most effective way to prevent hospitalization and death from COVID-19.” The results come from in person, phone and online surveys given to people who received two doses of the mRNA vaccine, three weeks apart, between February 16 and May 15, 2021. 1,183 people with a history of cancer responded to both surveys, with 17.8% then currently undergoing treatment. Respondents experienced pain at the injection site, muscle pain, joint pain, fever, chills, headache, nausea, and fatigue at similar rates as those reported by people without cancer from the original clinical trials. Adverse effects for people undergoing immunotherapy also mirrored those in the general population. “It’s crucial that cancer patients get vaccinated against COVID-19 because we know they can be particularly vulnerable to infection and its consequences, but some people have expressed concerns about possible reactions from the vaccines,” continued Dr. Horwitz. “Before this study, there wasn’t a lot of data specifically on the cancer population so we made sure to collect and report this information to help both patients and physicians make informed decisions to get mRNA vaccines.” “Getting vaccinated against COVID-19 was an opportunity for me to take control and help protect myself,” said Dan Burkus, who has received treatment from Fox Chase Cancer Center. “Undergoing cancer treatment and follow-up can be terrifying, especially during a pandemic. This new proof that people with cancer won’t have any extra side-effects from the mRNA vaccines is one less thing to worry about and one more reason to get the shot.” “The investigators convincingly showed no greater incidence of side-effects in patients with a history of cancer, and in fact recipients with a history of cancer had lower rates of pain at the injection site,” commented Natalie Callander, MD, University of Wisconsin Carbone Cancer Center, a member of the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis who was not involved in this research. “Over half the patients in this large prospective study had a history of cancer and about 18% were on active treatment. This study demonstrates that cancer patients experience no greater rate of complications and should help to counteract misinformation about COVID-19 vaccinations. This report provides additional reassurance to practitioners and patients that COVID-19 vaccines are safe and should be offered without hesitation, in accordance with CDC and NCCN recommendations.” To read the entire study, visit JNCCN.org. Complimentary access to “Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine” is available until May 10, 2022. Visit NCCN.org/covid-19 for more information on COVID-19 and cancer, including the latest recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. About JNCCN—Journal of the National Comprehensive Cancer Network More than 25,000 oncologists and other cancer care professionals across the United States read JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about innovation in translational medicine, and scientific studies related to oncology health services research, including quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit NCCN.org/jnccn/subscribe. Follow JNCCN on Twitter @JNCCN. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN. Logo – https://mma.prnewswire.com/media/441768/NCCN_Logo.jpg

(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)

Set up with an investment of Rs. 50 crore, Seedling aims to redefine conventional agriculture models

Greater Noida, Uttar Pradesh, India
Best Agrolife Limited (BAL), one of the leading agrochemicals in India, announced the commencement of production at its fully automated formulation facility Seedling India Pvt. Ltd. After the successful commissioning of the formulation facility, the production of high-end formulations has started well in time there. The manufacturing capacity of the facility is 18,000 MTPA.

Corporations can now translate their sustainability ambitions into action, with 10Impact’s end-to-end suite of CSR solutions

Innovative Financial Advisors Pvt. Ltd., a leading Delhi-based CSR consulting organisation, announced the launch of its new arm, 10Impact, to offer tailored, need-based CSR solutions specifically for corporations. Innovative Financial Advisors Pvt. Ltd., has worked with many corporations and civil society organisations, with the aim of making them more socially and environmentally responsible. Within fourteen years, since its inception in the year 2008, the organisation has emerged as one of the leading CSR services and solutions providers within the country.

10Impact, is an extension of Innovative Financial Advisor Pvt. Ltd.’s vision to develop a structural resource mobilisation strategy and a transparent framework within the CSR paradigm. Adapting practical tools and frameworks to capture the realities of the social-development sector of the country, 10Impact offers new CSR management tools which are an amalgamation of both human intelligence and technology, as a pivotal service, which corporations can leverage and capitalise for optimised project management efficiency. From developing CSR policies, to implementing and assessing impact of the social programmes, 10Impact will assist corporations achieve their corporate social responsibility goals, and ensure that the impact achieved is both socially responsible and profitable.

10Impact clocks a new chapter in Innovative Financial Advisor Pvt. Ltd.’s service diversification and growth trajectory.

Dr. Soumitro Chakraborty, CEO, Innovative Financial Advisors Pvt. Ltd., while speaking about the launch said, “India’s social-development sector is always the first one to get affected by any socio-economic or geo-political changes, and we have come to learn that arresting positive and negative effects of these changes is both imperative and essential. The COVID-19 pandemic cascaded an attitudinal shift within India Inc. and we saw corporations investing in innovative CSR solutions, aimed at achieving social inclusion and economic integration. In order to achieve their social welfare goals, the corporations require operational and implementation support, and it is this requirement that led to formation of 10Impact, and is also the goal that 10Impact aims to work towards.”

He further expressed his joy about the expansion and service diversification and stated, “It is indeed a proud moment for all of us. The greatest strength of any organisation is the belief of its people in its vision. We’ve been fortunate enough to enjoy the trust and undaunting support of all our employees, partners and various stakeholders. This provides us with the required inertia for the realisation of our cause and purpose.”

About Innovative Financial Advisors Pvt. Ltd.

Innovative Financial Advisors Pvt. Ltd. is a leading technical research agency operating in multiple disciplines of the social development sector with an emphasis on Corporate Social Responsibility (CSR) and Sustainability. It is focused towards enhancing quality across the organisational value chain through innovation. Since 2008, The organisation has grown phenomenally and has made a benchmark in the sector through its services. It’s research-based and scientific approach in Need Assessment, Project Implementation, Monitoring and Evaluation, and Impact Assessment has efficiently helped it to engage with corporations and civil society organisations for value-based CSR initiatives. The organisation has been assisting corporations through its research on policy drafting and implementation design to achieve competitive advantage in their respective arenas.

View article…

(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same.)

In its commitment to impart quality education for all students, Teach For India extends the deadline of its 2022 Fellowship

The Teach For India Fellowship is a 2-year, full-time, paid opportunity for India’s most promising individuals, both recent graduates, and working professionals, to serve as teaching Fellows to children in some of the nation’s most under-resourced schools. Recruitment for the 2022-2024 cohort will close tomorrow, on February 6th, 2022.

Come lead a classroom, be a part of the solution – Teach For India Fellowship deadline closes on February 6th, 2022

Through two years of the ‘Leadership as Teaching’ model, training, support, and on-ground exposure, Fellows Fellows will lead transformation change in the classroom in the short term, while developing critical leadership skills in the long term. Our Fellows will work across 260 schools across Delhi, Mumbai, Bengaluru, Pune, Hyderabad, Ahmedabad, and Chennai. The selected Fellows are placed as full-time teachers, for 2 years, in government or low-income private schools where they teach English, Mathematics, Science and Social Studies across Grades 1 to 10.

On the completion of this 2-year Fellowship, Teach For India Fellows become a part of a 4000+ members strong Alumni network of sector leaders and changemakers, which includes Safdar Rahman (Director of critically acclaimed film Chippa on Netflix); Anurag Kundu (Chairperson, Delhi Commission for Protection of Child Rights); Sharmili Phulgirkar (Senior Vice President, Citi); Aniket Doegar (Founder of Haqdarshak); Arja Dayal (Country Director, Innovations for Poverty Action); and Jigyasa Labroo (Co-Founder Slam out loud)

“What I find very attractive about Teach For India Fellowship is that it has the potential to change the educational inequity in India, and it has the potential to make leaders out of the Fellows who can not only get into a good position at work or join a university of their choice but transform their lives,” Arnavaz Aga, Founder Trustee – Teach For India.

In 2021, only 8.3% of the applicants who applied were selected. It has welcomed candidates from colleges such as Anna University (Chennai), NIT Suratkal (Mangalore), Stella Maris College (Chennai), St. Xavier’s College (Mumbai), The Maharaja Sayajirao University of Baroda, St. Stephens College (Delhi University) Thakur College of Science and Commerce (Mumbai), Patkar Varde College (Mumbai), University of Mysore, IIT Guwahati, University of Calcutta, Denison University (Ohio, US) and Leeds Beckett University among others. Fellows hail from corporations such as Citigroup, Deloitte, EY, Thomson Reuters, Citigroup, Tata Group, Wipro, and JP Morgan Chase.

Teach For India Alumni have widespread reach as they are cumulatively reaching more than 33 million children – or 1 in 10 children in India – through their work across schools, communities, policy, and various levels of the system

Now more than ever, we need young Indian citizens who can drive transformational change in the classrooms. Young people who will work closely with children with the greatest need, offer them opportunities towards a better future – and do all of this while pushing their own boundaries of leadership and civic engagement.

To apply, please visit: apply.teachforindia.org, check out this Video of the Impact of Fellowship

About Teach For India

Teach For India places outstanding working professionals and college graduates as Fellows – who work full-time as teachers for two years in low-income and under-resourced schools. With operations in Mumbai, Delhi, Hyderabad, Chennai, Pune, Ahmedabad, and Bangalore, Teach For India has over 970 Fellows impacting more than 32,000 children across the country. Post Fellowship, they join a growing movement of over 4000+ Alumni working at all levels of the education sector. A part of a global Teach For All network of 60 countries, with a shared vision of an excellent education for all children, Teach For India’s mission is to end educational inequity in India by creating a strong pipeline of driven, skilled talent within the educational ecosystem.

View article…

(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same.)

Sputnik Light will be an important part of India’s vaccination program and the fight against mutations of COVID, including Omicron.

Sputnik Light has been authorized in more than 30 countries with total population of over 2.5 billion people.

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the Russian one-shot Sputnik Light vaccine against coronavirus has been authorized by the Drug Controller General of India (DCGI).

Thus Sputnik Light has been registered in more than 30 countries with total population of over 2.5 billion people. A number of countries, including Argentina, Bahrain, UAE, San Marino and Philippines, have already authorized Sputnik Light as a universal booster.

A preliminary study of the Gamaleya Center has found that Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron, which is comparable to titers observed after Sputnik V against wild-type virus, associated with high levels of protection.

A unique comparative study[1] conducted at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center has shown that Sputnik V vaccine demonstrates more than 2 times higher titers of virus neutralizing antibodies to Omicron (B.1.1.529) variant than 2 doses of Pfizer vaccine (2.1 times higher in total and 2.6 times higher 3 months after vaccination).

The study was conducted in the equal laboratory conditions on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus neutralizing activity against Wuhan variant. Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).

Based on the data collected by the Spallanzani Institute and results of previous studies, heterologous (“mix & match”) boosting with Sputnik Light is the best solution to increase other vaccines’ efficacy and extend the booster protection period as optimal adenoviral platform configuration provides better protection against Omicron and other mutations.

Sputnik Light is based on recombinant human adenovirus serotype number 26 (the first component of Sputnik V). A one-shot vaccination regimen of Sputnik Light provides for ease of administration and helps to increase efficacy and duration of other vaccines when used as a booster shot.

Dr. Reddy’s Laboratories, a major partner of RDIF in India, has conducted local clinical trials of Sputnik Light in India. Positive data from these trials have been presented to India’s regulator and contributed to the positive decision by DCGI.

Clinical studies and the real-world data in many countries have demonstrated Sputnik Light is a safe and effective vaccine when used both on a standalone basis and as a booster.

A study in Argentina on heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino has demonstrated that each “vaccine cocktail” combination with Sputnik Light provided higher antibody titer on 14th day after administering the second dose as compared to original homogenous (same vaccine as first and second dose) regimens of each of the vaccines.

Sputnik Light will add to India’s national vaccine portfolio and join Sputnik V, which was approved in the country in April 2021. India is the leading production hub for Sputnik V.

Sputnik V and Sputnik Light are based on a safe and effective human adenoviral vector platform and have not been associated with rare serious adverse events following vaccination, such as myocarditis or pericarditis. The highest safety and efficacy of Sputnik V and Sputnik Light was demonstrated in more than 30 studies and real-world data from more than 60 countries.

Sputnik V has been authorized in 71 countries with total population of over 4 bn people. To facilitate the necessary production capacities, RDIF has reached agreements with the leading Indian pharmaceutical companies, including Serum Institute of India – the world’s largest vaccine producer, as well as Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“Authorization of Sputnik Light in India is another major step in successful cooperation between Russia and India in the fight against COVID. Sputnik Light has proven to be safe and effective both as a standalone vaccine and a universal booster shot to vaccines of other producers, helping to induce stronger immune response as compared to two shots of the same vaccine. The heterologous boosting approach using Sputnik Light is the solution to increase efficacy and duration of other vaccines, including against Omicron variant.”

Chennai, Tamil Nadu, India
Saveetha Oral Cancer Institute conducts a free cancer screening and awareness program in commemoration of world cancer day on 4th February 2022. Cancer becomes the second cause of death globally. Despite the tremendous developments in the field of diagnosis and treatment methods, the incidence of cancer has spiked in the last two decades in the Indian subcontinent. Being a pioneer as a dental college with a separate oral oncology unit, Saveetha dental college conducts free screening and treatment programs for the patients suffering from Oral cancer on World Cancer Day. With the latest technologies and skilful hands, Saveetha Oral Cancer Institute (SOCI) provides the utmost care for the patients. As the saying reveals, Prevention is better than cure, SOCI conducts camps to create awareness and aids in identifying the disease at a very early stage which leads to the best prognosis. While focusing on treatment, the preventive measures of such dreadful disease are also emphasized to the public.

MILPITAS, Calif., Feb. 5, 2022 /PRNewswire/ — SEMI, the industry association serving the global electronics design and manufacturing supply chain, today commended the passage of the America COMPETES Act of 2022 by the United States House of Representatives. The bill includes funding for the Creating Helpful Incentives to Produce Semiconductors for America (CHIPS) Act, earmarked to strengthen U.S. semiconductor manufacturing and research.

“We are very pleased to see the House pass the America COMPETES Act of 2022 including robust funding for the CHIPS Act programs,” said Ajit Manocha, SEMI president and CEO. “This bill also includes an important clarification to ensure equipment and materials suppliers can access the Section 9902 grant program. With this provision, the CHIPS programs will attract new manufacturing facilities – including chip fabs and facilities for back-end and upstream suppliers – and support technologies and innovation critical to numerous industries in the U.S. and around the globe. This bill will strengthen the semiconductor supply chain in the United States to meet the challenges of the twenty-first century as well as bolster crucial workforce development programs. We look forward to working with Congress and the Biden Administration to quickly enact this funding into law.”

“We continue to urge quick action on the Advanced Manufacturing Investment Credit and restoration of the ability to immediately deduct research expenses which was removed at the start of this year,” Manocha said.

Visit SEMI Global Advocacy to learn more about public policy efforts and developments, and SEMI Workforce Development for more information on efforts to address the microelectronics industry’s talent needs.

About SEMI

SEMI® connects more than 2,400 member companies and 1.3 million professionals worldwide to advance the technology and business of electronics design and manufacturing. SEMI members are responsible for the innovations in materials, design, equipment, software, devices, and services that enable smarter, faster, more powerful, and more affordable electronic products. Electronic System Design Alliance (ESD Alliance), FlexTech, the Fab Owners Alliance (FOA), the MEMS & Sensors Industry Group (MSIG) and SOI Consortium are SEMI Strategic Technology Communities. Visit www.semi.org to learn more, contact one of our worldwide offices, and connect with SEMI on LinkedIn and Twitter.

(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)

Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world

Sputnik V has been authorized in 71 countries with total population of over 4 billion people.

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that the Russian Sputnik V vaccine against coronavirus has been granted full permanent approval by Russia’s Health Ministry. It had previously held temporary emergency use authorization (EUA) from the Russian regulator.

Sputnik V was authorized on August 11, 2020, becoming the world’s first vaccine against COVID-19 to be granted emergency use authorization. Sputnik V has been authorized in 71 countries with a total population of over 4 billion people. Its one-component version, Sputnik Light, is authorized in over 30 countries, both as a standalone vaccine and a universal booster to other vaccines.

Sputnik V and Sputnik Light are based on a safe and effective human adenoviral vector platform and have not been associated with rare serious adverse events following vaccination, such as myocarditis or pericarditis. The highest safety and efficacy of Sputnik V and Sputnik Light was demonstrated in more than 30 studies and real-world data from more than 60 countries.

A unique comparative study[1] conducted at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center has shown that Sputnik V vaccine demonstrates more than 2 times higher titers of virus neutralizing antibodies to Omicron (B.1.1.529) variant than 2 doses of Pfizer vaccine (2.1 times higher in total and 2.6 times higher 3 months after vaccination).

The study was conducted in the equal laboratory conditions on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus neutralizing activity against Wuhan variant. Sputnik V showed significantly smaller (2.6 times) reduction of virus neutralizing activity against Omicron as compared to reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).

Based on the data collected by the Spallanzani Institute and results of previous studies, heterologous (“mix & match”) boosting with Sputnik Light is the best solution to increase other vaccines’ efficacy and extend the booster protection period as optimal adenoviral platform configuration provides better protection against Omicron and other mutations.

A preliminary study of the Gamaleya Center has found that Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron, which is comparable to titers observed after Sputnik V against wild-type virus, associated with high levels of protection.

Sputnik Light is based on recombinant human adenovirus serotype number 26 (the first component of Sputnik V). A one-shot vaccination regimen of Sputnik Light provides for ease of administration and helps to increase efficacy and duration of other vaccines when used as a booster shot.

Clinical studies and the real-world data in many countries have demonstrated Sputnik Light is a safe and effective vaccine when used both on a standalone basis and as a booster.

A study in Argentina on heterogeneous regimens combining Sputnik Light and vaccines produced by AstraZeneca, Sinopharm, Moderna and Cansino has demonstrated that each “vaccine cocktail” combination with Sputnik Light provided higher antibody titer on 14th day after administering the second dose as compared to original homogenous (same vaccine as first and second dose) regimens of each of the vaccines.

[1] https://www.medrxiv.org/content/10.1101/2022.01.15.22269335v1

– Acquisition of US FDA Approved State-of-the-Art Manufacturing Facility with Approximately 68,000 Square Feet On a 14 Acre Campus in the Heart of New Jersey – Also Known as “the Medicine Chest” of America

– Capabilities include Formulation Development, Manufacturing of Soft Gels, Powders, Tablets, Capsules, Liquid Drugs, Controlled Substance (schedule II – IV), Packaging, and Warehousing

– Enabling APNAR Pharma to Transition into a Fully Integrated Global Company with R&D, and Manufacturing in the United States of America as well as India

– Collaborative Business Model Allows APNAR Pharma to Provide Contract Manufacturing Services in Addition to Manufacturing APNAR Pharma’s Own Portfolio

EAST WINDSOR, N.J., Feb. 3, 2022 /PRNewswire/ — APNAR Pharma LP (APNAR) headquartered in Chino, CA has acquired East Windsor, NJ based Aurex Laboratories (Aurex) for an undisclosed amount. This acquisition enhances APNAR’s capabilities, scale, and global footprint and broadens APNAR’s pipeline.

Dharmesh Patel, President of APNAR said, “As part of our well-defined strategy and commitment of having manufacturing in the United States of America, we are excited to acquire Aurex. This milestone will position APNAR as a company with global footprint in the US and India.”

Sanjay Bhargav, COO of APNAR added, “In addition to adding state-of-the-art facility to APNAR’s capabilities in the US, we are pleased to welcome to APNAR an amazing team that is experienced, highly capable, and dedicated including scientists, manufacturing, regulatory, and project management personnel.”

“In addition to developing and manufacturing APNAR’s own products, we are looking forward to working in a collaborative manner with other companies for contract and co-development and contract manufacturing,” added Patel.

“We look forward to manufacturing APNAR’s 5 ANDAs and other drugs in the US to ensure supply chain security and excellence,” added Bhargav.

Nailesh Bhatt acted as a strategic advisor to both Aurex Laboratories and APNAR Pharma.

About APNAR Pharma LP

Headquartered in Chino, California, APNAR Pharma is a privately owned, rapidly growing pharmaceutical company. We develop, manufacture, package, sell, market, and distribute generic pharmaceuticals and OTCs. APNAR has R&D and manufacturing facilities in East Windsor, NJ, United States and Gavasad, Gujarat, India.

www.apnarpharma.com

(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same.)